STOCK TITAN
  1. Home
  2. Sec-filings
  3. MNPR
  4. [8-K] Monopar Therapeutics Reports Material Event

Monopar (NASDAQ: MNPR) meeting backs board, pay and 2026 plan

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Monopar Therapeutics Inc. held its Annual Meeting on June 22, 2026, with 6,698,778 common shares entitled to vote and 5,760,392 shares represented in person or by proxy. Stockholders voted on directors, executive compensation, the 2026 Stock Incentive Plan, and the 2026 auditor.

All six director nominees were elected, with support ranging from 4,203,485 to 4,911,758 votes for each candidate, plus broker non-votes. Stockholders approved the advisory vote on named executive officer pay and the Company’s 2026 Stock Incentive Plan, and ratified BPM LLP as independent registered public accounting firm for the year ending December 31, 2026.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Shares entitled to vote 6,698,778 shares Common stock entitled to vote as of April 27, 2026
Shares represented 5,760,392 shares Shares present in person or by proxy at Annual Meeting
Top director support 4,911,758 votes for Votes for director nominee Nicole Sweeny
NEO pay advisory approval 4,355,628 votes for Advisory vote on named executive officer compensation
2026 Stock Plan approval 4,444,209 votes for Approval of 2026 Stock Incentive Plan
Auditor ratification votes for 5,759,198 votes for Ratification of BPM LLP as auditor for year ending December 31, 2026
broker non-votes financial
"Director | For | Withheld | Broker Non-Votes Christopher M. Starr"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
advisory, non-binding basis financial
"approval of the compensation of the Company’s named executive offers on an advisory, non-binding basis"
2026 Stock Incentive Plan financial
"the approval of the Company’s 2026 Stock Incentive Plan"
independent registered public accounting firm financial
"to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001645469 0001645469 2026-06-22 2026-06-22
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): June 22, 2026
 
MONOPAR THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-39070
 
32-0463781
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
 
1000 Skokie Blvd., Suite 350, Wilmette, IL
 
60091
(Address of principal executive offices)
 
(Zip Code)
 
(847) 388-0349
Registrant’s telephone number, including area code
 
N/A
(Former name or former address, if changed since last report)
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common Stock, $0.001 par value
 
MNPR
 
The Nasdaq Stock Market LLC (Nasdaq Capital Market)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
1
 
Item 5.07 Submission of Matters to a Vote of Security Holders.
 
On June 22, 2026, Monopar Therapeutics Inc. (“Monopar” or the “Company”) held its Annual Meeting. A total of 6,698,778 shares of the Company’s common stock were entitled to vote as of April 27, 2026, the record date for the Annual Meeting, of which 5,760,392 shares were represented in person or by proxy at the Annual Meeting. At the Annual Meeting, the stockholders of the Company voted on the following proposals:
 
(1) the election of six directors to the Company’s Board of Directors to serve until the Company’s next annual meeting of stockholders or until their respective successors are duly elected and qualified; 
 
(2) the approval of the compensation of the Company’s named executive offers (“NEOs”) on an advisory, non-binding basis;
 
(3) the approval of the Company’s 2026 Stock Incentive Plan; and
 
(4) the ratification of the selection of BPM LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.
 
2
 
Proposal 1 - Election of Directors
 
At the Annual Meeting, the voting results with respect to the proposal for the election of directors, included in the Company’s Proxy Statement on Schedule 14A for the Annual Meeting, were as follows:
 
Director
For
Withheld
Broker Non-Votes
Christopher M. Starr, Ph.D.
4,203,485
757,652
799,255
Chandler D. Robinson, MD MBA MSc
4,447,108
514,029
799,255
Raymond W. Anderson, MBA MS
4,671,362
289,775
799,255
Kim R. Tsuchimoto
4,325,379
635,758
799,255
Lavina Talukdar, CFA
4,897,733
63,404
799,255
Nicole Sweeny
4,911,758
49,379
799,255
 
Accordingly, each of the foregoing persons was elected as a director at the Annual Meeting.
 
Proposal 2 - Approval of the Compensation of the Company’s Named Executive Officers on an Advisory, Non-Binding Basis
 
The voting results with respect to the proposal to approve the compensation of the Company’s NEOs on an advisory, non-binding basis, were as follows:
 
For
Against
Abstain
Broker Non-Votes
4,355,628
604,858
651
799,255
 
Accordingly, the Company’s stockholders approved the compensation of the Company’s NEOs on an advisory, non-binding basis.
 
Proposal 3 – Approval of the Company’s 2026 Stock Incentive Plan
 
The voting results with respect to the proposal to approve the Company’s 2026 Stock Incentive Plan were as follows:
 
For
Against
Abstain
Broker Non-Votes
4,444,209
516,570
358
799,255
 
Accordingly, the Company’s stockholders approved the Company’s 2026 Stock Incentive Plan.
 
Proposal 4 - Ratification of the Company’s Selection of Independent Registered Public Accounting Firm 
 
The voting results with respect to the proposal to ratify the selection of BPM LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026, were as follows:
 
For
Against
Abstain
Broker Non-Votes
5,759,198
998
196
N/A
 
Accordingly, the Company’s stockholders ratified the selection of BPM LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026.
 
No other matters were submitted to a vote of stockholders at the Annual Meeting.
 
3
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Monopar Therapeutics Inc.
 
 
 
 
 
Date: June 23, 2026
By:
/s/ Quan Vu
 
 
Name:
Quan Vu
 
 
Title:
Chief Financial Officer
 
 

Source: View Original Filing on SEC EDGAR

FAQ

What did Monopar Therapeutics (MNPR) shareholders vote on at the 2026 annual meeting?

Shareholders voted on electing six directors, approving executive compensation on an advisory basis, approving the 2026 Stock Incentive Plan, and ratifying BPM LLP as independent registered public accounting firm for the year ending December 31, 2026.

How many Monopar Therapeutics (MNPR) shares were represented at the 2026 annual meeting?

A total of 5,760,392 shares were represented in person or by proxy. This was out of 6,698,778 common shares entitled to vote as of April 27, 2026, the record date for the Annual Meeting.

Were all Monopar Therapeutics (MNPR) director nominees elected in 2026?

Yes, all six director nominees were elected. Each received more votes “For” than “Withheld,” with for-votes ranging from 4,203,485 to 4,911,758, along with 799,255 broker non-votes reported for each director.

Did Monopar Therapeutics (MNPR) shareholders approve the 2026 Stock Incentive Plan?

Yes, the 2026 Stock Incentive Plan was approved. Voting results showed 4,444,209 shares for, 516,570 against, 358 abstentions, and 799,255 broker non-votes, indicating overall support for the new stock incentive plan.

Was Monopar Therapeutics (MNPR) executive compensation approved on an advisory basis?

Yes, shareholders approved compensation for the named executive officers on an advisory, non-binding basis, with 4,355,628 votes for, 604,858 against, 651 abstentions, and 799,255 broker non-votes recorded.

Who is Monopar Therapeutics’ (MNPR) auditor for the year ending December 31, 2026?

Shareholders ratified BPM LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 5,759,198 votes for, 998 against, and 196 abstentions. There were no broker non-votes on this proposal.

Filing Exhibits & Attachments

4 documents

Other Documents